Aptus Pharma Launches Rs 13.02 Crore IPO on BSE SME Platform
Aptus Pharma, a pharmaceutical formulations company, has opened its IPO to raise Rs 13.02 crore. The offering of 18.6 lakh equity shares is priced between Rs 65-70 per share and will close on September 25. The company plans to list on the BSE SME platform on September 30. The IPO proceeds will be used for capital expenditure, working capital, and general corporate purposes. Aptus Pharma has shown significant revenue and profit growth in recent years, with a 38% increase in revenue and a 287.5% increase in profit after tax from FY24 to FY25.
*this image is generated using AI for illustrative purposes only.
Aptus Pharma, a pharmaceutical formulations company, has opened its Initial Public Offering (IPO) for subscription, aiming to raise Rs 13.02 crore. The IPO, which will close on September 25, offers 18.6 lakh equity shares priced between Rs 65-70 per share.
IPO Details
- Issue Size: Rs 13.02 crore
- Price Band: Rs 65-70 per share
- Subscription Period: Closes on September 25
- Listing Date: September 30 on BSE SME platform
- Market Capitalization: Rs 48.00 crore (at upper price band)
- Grey Market Premium: 10% over the upper price band
Share Allocation
The IPO's share allocation is structured as follows:
| Investor Category | Allocation Percentage |
|---|---|
| Qualified Institutional Buyers | 47.30% |
| Non-Institutional Investors | 14.30% |
| Retail Investors | 33.30% |
Company Overview
Aptus Pharma markets and distributes pharmaceutical formulations across 190 products in multiple therapeutic areas through four business verticals. The company has already raised Rs 3.70 crore from anchor investors on September 22.
Financial Performance
The company has shown significant growth in recent years:
| Financial Metric | FY24 | FY25 | Growth |
|---|---|---|---|
| Revenue | Rs 17.90 crore | Rs 24.60 crore | 38.00% |
| Profit After Tax | Rs 0.80 crore | Rs 3.10 crore | 287.50% |
Use of IPO Proceeds
The funds raised from the IPO will be utilized as follows:
- Rs 1.60 crore for capital expenditure
- Rs 8.00 crore for working capital
- Remaining amount for general corporate purposes
Investors interested in the pharmaceutical sector and SME stocks may consider this offering, keeping in mind the risks associated with investing in newly listed companies on the SME platform.
16
